Skip to main content
. Author manuscript; available in PMC: 2015 Jan 20.
Published in final edited form as: Virology. 2013 Dec 5;449:163–173. doi: 10.1016/j.virol.2013.10.035

Figure 4.

Figure 4

Blood biocompatibility assays. (A) Red blood cell (RBC) hemolysis assay. (B) Zoomed in RBC hemolysis assay showing Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP do not lyse RBCs. (C) Effect of Cy5-TMV, PEG-Cy5-TMV, and Cy5-SNP on clotting (normalized to saline control), measured in rotational thromboelastometry (ROTEM). There were no significant changes in the combined clotting time (CT+CFT) and maximum clot firmness (MCF) compared to the saline control (dotted line). Error bars represent S.D.